The Market Reports

Synopsis

The global market for Human Coagulation Factor VIII was estimated to be worth US$ 11550 million in 2024 and is forecast to a readjusted size of US$ 17610 million by 2031 with a CAGR of 6.3% during the forecast period 2025-2031.

Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P®), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis.

Market Drivers:

The increasing prevalence of hemophilia A is a key driver for the Human Coagulation Factor VIII market. As awareness and diagnosis rates improve, more patients are receiving proper treatment, driving demand for Factor VIII therapies. Additionally, advancements in biotechnology, including the development of recombinant and extended half-life Factor VIII products, have significantly improved treatment efficacy and patient convenience. Government initiatives and healthcare programs supporting rare disease treatments, along with expanded access to hemophilia care in developing regions, further boost market growth. The rise of gene therapy research also presents potential future opportunities for transforming the hemophilia treatment landscape.

Market Challenges:

Despite strong market growth, several challenges persist, including the high cost of Factor VIII therapies, which limits affordability and accessibility for many patients, especially in low-income regions. Additionally, plasma-derived Factor VIII products face supply chain constraints due to reliance on blood donations. Another major challenge is the development of inhibitors (antibodies) in some patients, which can render Factor VIII treatment ineffective and necessitate alternative therapies.

Regulatory complexities and the need for stringent quality control in manufacturing also pose barriers for new entrants in the market.

This report aims to provide a comprehensive presentation of the global market for Human Coagulation Factor VIII, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Human Coagulation Factor VIII by region & country, by Type, and by Application.

The Human Coagulation Factor VIII market size, estimations, and forecasts are provided in terms of sales volume (K Bottles) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Coagulation Factor VIII.

Market Segmentation

By Company

• Takeda
• Bayer
• CSL
• Pfizer
• Grifols
• Biogen
• Octapharma
• NovoNordisk
• Greencross
• Kedrion
• BPL
• Hualan Bio
• RAAS
• SinoCellTech
• Taibang Bio
• Huarun Boya
• Shuanglin Bio
• Yuandashuyang
• Weiguang Bio

Segment by Type

• Recombinant Factor VIII
• Plasma-derived Factor VIII

Segment by Application

• Hemophilia A
• Spontanous / Trauma
• Surgical
• Other

Segment by Region

• North America: United States, Canada, and Mexico
• Europe: United Kingdom, Germany, France, Spain, Italy, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, and Rest of Asia Pacific
• Middle East & Africa: Saudi Arabia, South Africa, and Rest of MEA
• Latin America: Brazil, Argentina, and Rest of Latin America

*If you need a regional or country-specific version, or customized segmentation, we can tailor the report to your requirements.